Ovarian Cancer Drugs Market
Global Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2022-2028)
The global ovarian cancer drugs market is anticipated to grow at a significant CAGR of 13.8% during the forecast period. The market is backed by the growing adoption of novel drugs and strong pipeline products. Increasing incidences of ovarian cancer across the globe is one of the major factors that contribute to the growth of the market. According to the World Cancer Research Fund (WCRF), ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall. There were more than 313,000 new cases of ovarian cancer in 2020. Thus, the rising incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.
Impact of COVID-19 Pandemic on Global Ovarian Cancer Drugs Market
COVID-19 pandemic has moderately hampered the growth of the pharmaceutical industry. The disorder in global supply chains and trade barriers all over the world impacted the oncology community with exceptional challenges. Patients suffering from ovarian cancer (OC) have been affected by a delay in diagnosis, chemotherapy, surgery and radiation treatments, and oncology follow-ups being performed via telemedicine instead of in-person visits during the COVID -19 pandemic. As a result OC patients and their oncologists faced the consequences of delayed cancer care.
Segmental Outlook
The global Ovarian Cancer Drugs market is segmented based on the drug class, and therapy. Based on the drug class, the market is segmented into PARP inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors. Based on, the therapy the market is sub-segmented into the chemotherapy, targeted therapy, immunotherapy, and others. The above-mentioned segments can be customized as per the requirements. Among the drug class segment, the angiogenesis inhibitors sub-segment is expected to cater considerable growth over the forecast period, due to growing competition from PARP inhibitors and novel pipeline products.
Global Ovarian Cancer Drugs Market Share by Therapy, 2021 (%)
The Chemotherapy Sub-Segment is Anticipated to Hold Prominent Share in the Global Ovarian Cancer DrugsMarket
Based on, the therapy, Chemotherapy segment is projected to have a significant market share during the forecast period. The market is growing due to the rising adoption of chemotherapy and drugs combination in the treatment of ovarian cancer. Chemotherapy is the method that uses drugs to destroy cancer cells and reduce the growing ability of the cancer cells. The most common ways to give chemotherapy include an intravenous tube that is placed into a vein using a needle under the skin (subcutaneous) or into a muscle (intramuscular), swallowed the drug and capsule. There are various drugs such as Albumin bound paclitaxel, Altretamine, Capecitabine, Cyclophosphamide and others that can be used in chemotherapy for the treatment of ovarian cancer.
Regional Outlooks
The global Ovarian Cancer Drugsmarket is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for particular region or country level as per the requirement. Among these, the European regional market is expected to cater considerable growth over the forecast period, owing to rising burden of cancer coupled up with raising need for effective treatment in this region
Global Ovarian Cancer Drugs Market Growth, by Region 2022-2028
The North America Region is Expected to Hold Prominent Share in the Global Ovarian Cancer Drugs Market
The North America region is expected to hold a prominent share in the global Ovarian Cancer Drugs market owing to. Rising R&D in cancer research and a significant prevalence of ovarian cancer across in the US are driving the market. As per Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, in 2019, there were an estimated 233,565 women living with ovarian cancer in the US. Ovarian cancer is the thirteenth leading cause of cancer death in the US. The death rate was 6.5 per 100,000 women per year based on 2015–2019, age-adjusted. Moreover, increasing healthcare expenditure and rising awareness regarding cancer is further driving the market growth in the region.
Market Players Outlook
The major companies serving the global ovarian cancer drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In 2019, GlaxoSmithKline plc announced that it has successfully completed the acquisition of TESARO, Inc. a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global ovarian cancer drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Ovarian Cancer Drugs Market
• Recovery Scenario of Global Ovarian Cancer Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. AstraZeneca PLC
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Clovis Oncology, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. F. Hoffmann-La Roche Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. GlaxoSmithKline PLC
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Merck & Co., Inc.
3.6.1. Overview
3.6.2. Financial Analysis
3.6.3. SWOT Analysis
3.6.4. Recent Developments
3.7. Key Strategy Analysis
3.8. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Ovarian Cancer Drugs Market by Drug Class
4.1.1. PARP Inhibitors
4.1.2. Angiogenesis Inhibitors
4.1.3. PD-L1 Inhibitors
4.2. Global Ovarian Cancer Drugs Market by Therapy
4.2.1. Chemotherapy
4.2.2. Targeted Therapy
4.2.3. Immunotherapy
4.2.4. Others (Hormonal Therapy)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Amgen Inc.
6.2. AbbVie Inc.
6.3. Boehringer Ingelheim GmbH
6.4. Bristol-Myers Squibb Co.
6.5. DelMar Pharmaceuticals, Inc.
6.6. Eli Lilly and Co.
6.7. Exelixis, Inc.
6.8. Genentech, Inc.
6.9. ImmunoGen Inc.
6.10. Janssen Global Services, LLC, a division of Johnson & Johnson Services, Inc,
6.11. Mersana Therapeutics, Inc.
6.12. Oasmia Pharmaceutical AB
6.13. OncBioMune Pharmaceuticals Inc.
6.14. Pfizer Inc.
1. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
2. GLOBAL PARP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ANGIOGENESIS INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL PD-L1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
6. GLOBALOVARIAN CANCER DRUGS IN CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OVARIAN CANCER DRUGS IN TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL OVARIAN CANCER DRUGS IN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL OVARIAN CANCER DRUGS IN OTHER THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
13. NORTH AMERICAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
14. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
16. EUROPEAN OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
22. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL OVARIAN CANCER DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL OVARIAN CANCER DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL OVARIAN CANCER DRUGS MARKET, 2022-2028 (%)
4. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
5. GLOBAL PARP INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL ANGIOGENESIS INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL PD-L1 INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY THERAPY, 2021 VS 2028 (%)
9. GLOBAL OVARIAN CANCER DRUGS IN CHEMOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OVARIAN CANCER DRUGS IN TARGETED THERAPYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL OVARIAN CANCER DRUGS IN IMMUNOTHERAPYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL OVARIAN CANCER DRUGS IN OTHER THERAPIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. US OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. UK OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. REST OF EUROPE OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
